Explore FHI 360

Published research

Safety and tolerability of maraviroc-containing regimens to prevent HIV infection in women: A phase 2 randomized trial

This study shows that, for U.S. women at risk of HIV infection, pre-exposure prophylaxis (PrEP) regimens containing maraviroc are safe and well-tolerated, compared with the standard regimen of tenofovir disoproxil fumarate/emtricitabine. The authors also found that no new infections occurred with the study regimen, compared with the standard regimen, but more research is needed to determine whether that outcome is because of the study drug and whether the enrolled population was lower risk than anticipated.

You are here

Search FHI 360

Practice Areas

Services

Content Types

Expertise Areas

Countries

Resource Types

Trust in the provider and accurate self-reported PrEP adherence among adolescent girls and young women in South Africa and Zimbabwe: HPTN 082 study

Examining associations between mental health, IPV exposure, HIV risk behaviors, and PrEP use in South African women: an analysis of data from the Charisma Study

Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study)

Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial

Safety and tolerability of maraviroc-containing regimens to prevent HIV infection in women: A phase 2 randomized trial

Medical Education Resource Africa (MERA)

You are here

Search FHI 360

Practice Areas

Services

Content Types

Expertise Areas

Countries

Resource Types

Search within these results

6 Results Found

Trust in the provider and accurate self-reported PrEP adherence among adolescent girls and young women in South Africa and Zimbabwe: HPTN 082 study

Examining associations between mental health, IPV exposure, HIV risk behaviors, and PrEP use in South African women: an analysis of data from the Charisma Study

Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study)

Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial

Safety and tolerability of maraviroc-containing regimens to prevent HIV infection in women: A phase 2 randomized trial

Medical Education Resource Africa (MERA)